title: International society for antiviral research - 23rd international conference.
abstract: The 23rd International Conference on Antiviral Research (ICAR), organized by the International Society for Antiviral Research (ISAR) and held in San Francisco, included topics covering new therapeutic developments in the field of antivirals. This conference report highlights selected presentations on CD4-BFFI (Roche Holding AG), a CD4 mAb-based bifunctional HIV entry inhibitor; a CLDC-HBsAg vaccine (Juvaris BioTherapeutics Inc/China National Biotec Group) against HBV; ODE-(S)-MPMPA (University of California San Diego), a potent anti-HCV compound; the anti-human CMV activity exhibited by tricin; the protective activity of Ingavirin against influenza A; and Prosetta Bioconformatics's approach to identifying small-molecule antivirals.
authors.affiliation: Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. vicki.mason@thomsonreuters.com
authors.forename: Vicki L
authors.initials: VL
authors.lastname: Mason
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000276:immunology; D015195:Drug Design; D015507:Drugs, Investigational; D023581:HIV Fusion Inhibitors / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects*; D006509:Hepatitis B / Q000188:drug therapy; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects; D013678:Technology, Pharmaceutical; D014761:Viral Hepatitis Vaccines
chemical_list: D000998:Antiviral Agents; D015704:CD4 Antigens; D015507:Drugs, Investigational; D023581:HIV Fusion Inhibitors; D014761:Viral Hepatitis Vaccines